Company BenevolentAI

Equities

BAI

LU2355630455

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for BenevolentAI

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Euronext Amsterdam Other stock markets 08:35:47 03/05/2024 pm IST			5-day change	1st Jan Change
0.616 ^EUR	-3.75%		-5.23%	-42.96%

02/05	Benevolentai S.A. Announces Directorate Changes	CI
15/04	BenevolentAI S.A. Announces Board Resignations, Effective from May 2, 2024	CI

BenevolentAI is a leader in applying advanced AI to accelerate biopharma drug discovery. The Company serves patients by leveraging its proprietary and validated Benevolent PlatformTM that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery.

The Company's business model presents multiple routes for value creation including discovery collaborations with pharma companies like AstraZeneca and Merck, and advancing in-house pipelines to inflection points.

Number of employees: 248

Managers	Title	Age	Since
Ivan Griffin FOU	Founder	48	01/13/01
Catherine Isted DFI	Director of Finance/CFO	-	11/23/11
Francois Nader CHM	Chairman	67	22/22/22
Constantinos Neophytou CTO	Chief Tech/Sci/R&D Officer	-	01/20/01
Anne Phelan CTO	Chief Tech/Sci/R&D Officer	59	01/19/01
Fleur Wood IRC	Investor Relations Contact	-	-
Anna Fullerton Batten HRO	Human Resources Officer	-	01/22/01
Christina Busmalis PRN	Corporate Officer/Principal	-	18/23/18
Catherine Tucker PRN	Corporate Officer/Principal	-	01/19/01
William Scrimshaw LAW	General Counsel	-	01/19/01

Members of the board	Title	Age	Since
Francois Nader CHM	Chairman	67	22/22/22
Olivier Brandicourt BRD	Director/Board Member	68	22/22/22
Nigel Shadbolt BRD	Director/Board Member	68	01/20/01
Jean Raby BRD	Director/Board Member	60	22/22/22
John Orloff BRD	Director/Board Member	66	01/21/01
Marcello Damiani BRD	Director/Board Member	54	04/23/04
Susan Liautaud BRD	Director/Board Member	-	01/22/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	142,626,303	75,652,018 ( 53.04 %)	20,686,419 ( 14.50 %)	53.04 %

Name	Equities	%	Valuation
Kenneth Patrick Mulvany 23.78 %	33,912,333	23.78 %	25 M €
Michael Brennan 3.239 %	4,619,160	3.239 %	3 M €
Jean Raby 0.4570 %	651,745	0.4570 %	471 603 €
DNCA Finance SA 0.3196 %	455,832	0.3196 %	329 840 €
Olivier Brandicourt 0.3046 %	434,495	0.3046 %	314 401 €
Ann Hunter 0.1349 %	192,465	0.1349 %	139 268 €

Name	Equities	%	Valuation
Evelyn Partners Investment Management LLP 0.4000 %	40,000	0.4000 %	432 €
Decalia SA 0.3060 %	30,600	0.3060 %	330 €
Evelyn Partners Fund Solutions Ltd. 0.2000 %	20,000	0.2000 %	216 €

BenevolentAI SA

4-8 Maple Street

W1T 5HD, London

http://www.benevolent.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.548 GBP

Average target price

1.632 GBP

Spread / Average Target

+197.83%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
BENEVOLENTAI	-42.59%	83.49M
MODERNA, INC.	+26.28%	48.09B
IQVIA HOLDINGS INC.	-3.99%	40.43B
LONZA GROUP AG	+46.79%	40.62B
CELLTRION, INC.	-6.20%	28.36B
ICON PUBLIC LIMITED COMPANY	+6.36%	24.89B
ALNYLAM PHARMACEUTICALS, INC.	-21.47%	19.01B
MEDPACE HOLDINGS, INC.	+27.58%	12.09B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.75%	11.8B
BIO-TECHNE CORPORATION	-2.02%	11.88B

Other Biotechnology & Medical Research